source
- AstraZeneca and Ionis report unexpected failure of heart disease drug in trialAstraZeneca and Ionis disclosed that their collaborative heart disease drug did not meet primary endpoints in a recent trial, marking a surprise setback. The companies detailed the trial results,…
- Roche commits over $1 billion to DualityBio for ADC development targeting TOP1 resistanceRoche's Genentech unit announced a major investment in DualityBio to advance antibody-drug conjugate (ADC) technology. Under the agreement DualityBio will receive an upfront payment of $45 million…